Novartis Voluntary Nationwide Recalls Three Lots of Promacta (eltrombopag, 12.5 mg) Oral Suspension Due to Peanut Contamination


  • Novartis recalls three lots of Promacta oral suspension to the consumer level due to the presence of peanut floor contamination occurred at third-party manufacturing facility and is conducted within the knowledge of the US FDA
  • The voluntary recall is done for the lot numbers 8H57901589, 9H57900189 & 9H57900289 with no reported adverse event till date. The Promacta 12.5 mg, 25 mg, 50 mg, 75 mg tablets have no impact of the recall
  • Promacta (eltrombopag, 12.5 mg,) is a TPO receptor agonist and is indicated for the treatment of chronic immune thrombocytopenia, severe aplastic anemia with no prior immunosuppressive therapy in adults & pediatric patients, also indicated for hepatitis C-associated thrombocytopenia in adults only

 Click here to read full press release/ article | Ref: Novartis | Image: Jekseng